University of Patras
Μοριακά δίκτυα δυνητικών stem κυττάρων στο κακοήθες μελάνωμα του δέρματος
Abstract
dc:descriptionBackground. Cutaneous malignant melanoma originates from melanocytes and is characterized by constantly growing incidence and mortality rates world-wide. The substantial unresponsiveness of advanced metastatic melanomas to most forms of chemotherapy and radiation indicates an urgent need for more effective agents to overcome chemoresistance. The field of cancer systems biology has emerged to address the increasing challenge of cancer as a complex, multifactorial disease using sophisticated model-based approaches. Accumulating evidence strongly suggests the presence and involvement of cancer cells with stem cell-like properties (CSCs) in the initiation, progression and metastasis of malignant melanoma. The emerging concept of cell plasticity and reciprocity (to change the phenotype by processing signals from the environment) throws more light on the actual complexity of tumor heterogeneity. The discovery that the epithelial to mesenchymal transition (EMT) generates cells with stem cell-like properties and a more invasive and metastatic phenotype, brings a connection between metastasis and the stem-cell state. According to this model, cells with stem cell properties are located predominantly at the tumor invasion front (IF) and can derive through the acquisition of transient EMT phenotype. SOX2 and Oct4 represent crucial components of the reciprocal regulatory circuit that controls stemness. The misregulation of epigenetic modifications, such as H3K4me2 and H3K27me3 which constitute stem cell-like "bivalent" domains, have been also identified to possess a crucial role in carcinogenesis. Polycomb-group proteins proteins and mainly EZH2 are responsible for maintaining the balance of the bivalent chromatin domain through the methylation of H3K27. Purpose. Taking these data into account, we performed the current study in order to evaluate the immunohistochemical expression of EZH2, SOX2 and Oct4 as well as H3K4me2 and H3K27me3, which constitute stem cell-like "bivalent"domains, in cutaneous malignant melanoma, investigating besides the potential identification of cancer cells with stem cells properties at the invasion front of the tumor. Materials and methods. Expression of EZH2, SOX2, Oct4, H3K4me2 and H3K27me3 was evaluated in 89 malignant melanoma (MM) lesions, deriving from 79 patients, using immunohistochemistry, on formalin-fixed paraffin-embedded tissue sections. The analyzed cases were accessioned over the time interval 2001- 2010 and retrieved from an electronic database maintained by the Department of Pathology of the University General Hospital of Patras (Rion, Greece). 14 specimens contained both melanoma cells and nevus cells. Analysis and comparative studies were carried out on the expression of the proteins tested in melanoma cells, nevus cells (where existed), and keratinocytes. In cases where staining was heterogeneous, as at the tumor IF, immunostaining was evaluated both for the inner tumor mass and241the IF. Polymer based technique (Envision, Dako, USA) or MACH4 Universal HRP-Polymer Detection (Biocare Medical, USA) and primary antibodies against EZH2 (Novocastra Laboratories Ltd, UK), SOX2 (R&D Systems, Inc.), Oct4 (Santa Cruz Biotechnology, Inc), H3K4me2 (Cell Signaling Technology, USA) and H3K27me3 (Cell Signaling Technology, USA) were used. In each case, the percentage of cells exhibiting positive staining was determined. Cell counts were performed at a 400X magnification. Data were analyzed using the SPSS statistical package (SPSS©, Release 19.0). The level of significance was set at p-value < 0.05.Results.EZH2, H3K4me2 and H3K27me3 were identified in the cell nuclei of melanoma cells, nevus cells and epidermal keratinocytes, while the stemness markers SOX2 και Oct4 showed, in contrast to previous studies, nuclear and cytoplasmic expression. In general, a specific distribution pattern of H3K4me2 and H3K27me3 was found, as stronger levels were localized at the tumor IF compared to the inner tumor mass(p=0.035 and p<0.010 respectively). A similar trend was also observed for EZH2, without achieving however statistical significance (p=0.080), and similarly for SOX2 in a few sporadic cases. Statistical analysis further revealed significantly higher expression of EZH2 in melanoma cells compared to nevus cells, while nuclear SOX2 and Oct4 expression was found increased in nevus compared to melanoma cells (p=0.003 and p=0.004 respectively). H3K4me2 and H3K27me3 nuclear levels presented significantly higher values in primary with respect to metastatic melanoma lesions (p=0.006 and p=0.030 respectively). Advanced melanoma demonstrated significantly lower H3K4me2 expression than did cases of lowest Clark level (I) or low Breslow depth (p=0.040 and p<0.001 respectively). As far as nuclear expression of Sox2 is concerned, its nuclear LIs in melanoma cells presented significantly higher values in primary compared to metastatic malignant melanoma lesions (p=0.045) as well as in melanoma cells with low Breslow’s depth (≤1mm) (p=0.045), in the absence of ulceration (p=0.010) and with low (≤6/mm2) mitotic rate (p=0.015). A significant difference between the LIs in melanoma cells under the presence or absence of lymphocytic infiltration was found, as lymphocytic infiltration was associated with significantly expression of EZH2 in melanoma cells (p=0.015). Finally, statistical analysis further revealed a positive correlation in melanoma cells between expression levels of EZH2 and H3K27me3 (p=0.030), H3K4me2 and H3K27me3 (p<0.010), Oct4 and SOX2 (p<0.001), SOX2 and H3K4me2 (p=0.005) as well as Oct4 and H3K27me3(p=0.004). Conclusions.Our results suggest the possibility that combined immunohistochemical expression of EZH2, SOX2, Oct4, H3K4me2 and H3K27me3 might identify cancer cells with potential stem cell properties, particularly at the invasion front of this malignancy. Moreover, these factors may play an important role in the pathogenesis of cutaneous malignant melanoma. These hypotheses should be further investigated, as many of the epigenetic changes are reversible via pharmacologic manipulations and new CSC-directed therapies, overpassing the resistance of advanced melanoma, may be developed.
Degree
thesis:*- Grantor dc:publisher
- University of Patras
- Year dc:date
- 2014
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Kampilafkos, Panagiotis
- Καμπιλαυκός, Παναγιώτης
Subjects
dc:subject × 8Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/35863